Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2
This expert-led discussion captures proceedings from one of a series of visiting professorship programs to support specialists in the introduction of recently approved and emerging antibody drug conjugates to address unmet needs in the treatment of metastatic TNBC. This activity also includes patient cases that incorporate the latest evidence. Excerpts from the live Q&A session and downloadable TNBC resources are also provided.
Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2Expert Perspectives
Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.
Faculty: Sara Hurvitz, MD, FACP
Expiration Date: December 23, 2022
CME/CE is no longer available for this activity